Evidence check: Fertility Check in the context of longevity

A Fertility Check marketed within a longevity panel lacks robust scientific validation. While markers like AMH, FSH, and estradiol can indicate ovarian reserve, their direct link to overall lifespan or biological aging is weak. Most commercial tests combine these biomarkers without validated longitudinal data or established reference ranges for 'optimal fertility' in a longevity context. Evidence is primarily associative (GWAS) or mechanistic, not from interventional trials. A fertility check may serve as a screening tool for reproductive health, but it should not guide anti-aging interventions. Caveat: hormonal fluctuations, cycle timing, and lifestyle factors (age, BMI, smoking) have stronger effects than genetic variants. Consult a reproductive endocrinologist before using such results to justify supplements or hormone therapies. The longevity framing is largely marketing; true longevity biomarkers (e.g., epigenetic clocks, telomere length) are distinct and not interchangeable with fertility markers.